The escalating presence of the H5N1 avian influenza virus, commonly referred to as bird flu, within animal populations, including recent widespread transmissions into dairy herds in the United States, has amplified concerns regarding its potential for zoonotic spillover and subsequent human-to-human transmission. This virus, first identified in American poultry in 2014, has demonstrated an evolving capacity to move beyond its wild bird reservoirs, establishing itself in domestic livestock and consequently presenting an increasing risk to human health. Since 2022, the Centers for Disease Control and Prevention (CDC) has reported over seventy human infections with H5N1 in the U.S., tragically resulting in two fatalities, underscoring the urgency of developing robust preventative measures. The ongoing circulation of H5N1 among diverse animal species fuels scientific apprehension about its potential to acquire genetic mutations that could facilitate more efficient spread among humans, thereby posing a significant threat of a global pandemic.
In a proactive effort to mitigate the risk of widespread human infection and a potential pandemic, a collaborative team of scientists at Washington University School of Medicine in St. Louis has engineered and rigorously tested an innovative vaccine administered intranasally, offering an alternative to conventional intramuscular injections. This pioneering approach, detailed in a recent publication in Cell Reports Medicine, has yielded promising results in preclinical studies involving hamsters and mice, where the intranasal vaccine elicited substantial immune responses and proved highly effective in preventing H5N1 infection following viral exposure.
A critical hurdle in the development of effective influenza vaccines, particularly for novel strains like H5N1, lies in overcoming the challenge posed by pre-existing immunity. Individuals often possess immunological memory derived from prior seasonal influenza infections or vaccinations, which can sometimes attenuate the protective efficacy of new influenza vaccine candidates. The researchers specifically addressed this challenge, finding that their intranasal H5N1 vaccine maintained its robust protective capabilities even in animal models that had previously acquired immunity to seasonal flu strains. This finding is particularly significant for real-world application, as the vast majority of the population, excluding very young children, carries some level of immune history related to influenza viruses.
The development of this novel vaccine builds upon a well-established intranasal vaccine platform previously refined at Washington University School of Medicine. This platform has demonstrated success in other viral contexts, notably contributing to a COVID-19 vaccine that has been available in India since 2022 and received approval for clinical trials in the United States last year. The research team, led by professors Jacco Boon, Michael S. Diamond, and David T. Curiel, leveraged this existing technological foundation to create a more potent and accessible defense against H5N1.
Professor Jacco Boon, a co-senior author of the study and a professor in the Department of Medicine at WashU Medicine, emphasized the critical juncture presented by the recent zoonotic jump of H5N1 into dairy cows. He stated, "This particular version of bird flu has been around for some time, but the unique and totally unexpected event where it jumped across species into dairy cows in the United States was a clear sign that we should prepare for the event that a pandemic may occur." He further elaborated on the advantages of their nasal delivery system: "Our vaccine to the nose and upper airway—not the shot-in-the-arm vaccine people are used to—can protect against upper respiratory infection as well as severe disease. This could provide better protection against transmission because it protects against infection in the first place."
To construct a vaccine that elicits a precisely targeted immune response against H5N1, Boon and co-author Eva-Maria Strauch, an associate professor of medicine specializing in antivirals and protein design, meticulously selected proteins from H5N1 strains known to infect humans. By identifying conserved features within these viral proteins, they engineered an optimized antigen—the specific component of a pathogen that triggers an immune response. This meticulously designed antigen was then incorporated into a harmless, non-replicating adenovirus, which functions as a sophisticated delivery vehicle for the vaccine. This methodology for antigen design and adenovirus-mediated delivery closely mirrors the successful strategy employed for the aforementioned COVID-19 intranasal vaccine.
The efficacy of this intranasal H5N1 vaccine was rigorously evaluated in animal studies. In both hamster and mouse models, administration of the nasal spray vaccine resulted in near-complete protection against H5N1 infection. As anticipated, conventional seasonal flu vaccines offered minimal protection against the avian influenza strain. Crucially, the intranasal vaccine demonstrated superior protection compared to the same vaccine delivered via a traditional intramuscular injection in both animal models. The vaccine’s resilience was further highlighted by its high effectiveness even when administered at reduced doses and subsequently challenged with substantial viral loads, underscoring its potent protective capabilities under demanding conditions.
A significant benefit of delivering the vaccine directly to the nasal passages is the induction of strong immune responses not only systemically but also with pronounced activity within the nasal cavities and the broader respiratory tract. Professor Diamond, another co-senior author of the study, highlighted this advantage: "We’ve shown that this nasal vaccine delivery platform we conceived, designed and conducted initial testing on at WashU Medicine can prevent H5N1 infection from taking hold in the nose and lungs." He further elaborated on the implications for transmission control: "Delivering vaccine directly to the upper airway where you most need protection from respiratory infection could disrupt the cycle of infection and transmission. That’s crucial to slowing the spread of infection for H5N1 as well as other flu strains and respiratory infections."
The research team also conducted supplementary experiments to ascertain whether prior exposure to influenza viruses, through infection or vaccination, would impede the H5N1 vaccine’s performance. Their findings indicated that the intranasal vaccine consistently provided robust protection, even in the presence of pre-existing immunity to seasonal flu. This characteristic is of paramount importance for the practical deployment of the vaccine, given the widespread immune memory present in most populations.
Looking ahead, the research team is committed to further advancing the development of this promising H5N1 vaccine. Their future plans include conducting additional studies in animal models and utilizing organoids—laboratory-grown tissues that mimic human organ structures—to model human immune responses. Furthermore, efforts are underway to develop refined versions of the vaccine, specifically engineered to further minimize the impact of pre-existing seasonal flu immunity and to enhance the body’s antiviral defense mechanisms. The research was supported by grants from the Cooperative Center for Human Immunology and the Center for Research on Structural Biology of Infectious Diseases. The Boon laboratory has received research funding from Novavax Inc. for influenza vaccine development and unrelated funding from AbbVie Inc., while the Diamond laboratory has received unrelated funding through sponsored research agreements from Moderna. Professor Diamond also serves as a consultant or on the Scientific Advisory Board for several biotechnology and pharmaceutical companies, including Inbios, IntegerBio, Akagera Medicines, GlaxoSmithKline, Merck, and Moderna.
About the Author
